VEGFA and neoplasm: The evasion of tumor from therapies targeting the VEGFA/VEGFR axis may be attributed to several factors: increased activation of EGFR; the development of lymphangiogenesis which provides an additional route for metastatic dissemination; the production of compensatory pro-angiogenic factors (FGF, VEGFB, angiopoietins, cytokines of the ELR+CXCL family) to counteract the effects of VEGFA inhibition (Figure 5).